Mirtazapine provokes periodic leg movements during sleep in young healthy men. 2013

Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
Max Planck Institute of Psychiatry, Munich, Germany. stephany.fulda@gmail.com

OBJECTIVE Recent evidence suggests that certain antidepressants are associated with an increase of periodic leg movements (PLMS) that may disturb sleep. So far, this has been shown in patients clinically treated for depression and in cross-sectional studies for various substances, but not mirtazapine. It is unclear whether antidepressants induce the new onset of PLMS or only increase preexisting PLMS, and whether this is a general property of the antidepressant or only seen in depressed patients. We report here the effect of mirtazapine on PLMS in young healthy men. METHODS Open-labeled clinical trial (NCT00878540) including a 3-week preparatory phase with standardized food, physical activity, and sleep-wake behavior, and a 10-day experimental inpatient phase with an adaptation day, 2 baseline days, and 7 days with mirtazapine. METHODS Research institute. METHODS Twelve healthy young (20-25 years) men. METHODS Seven days of nightly intake (22:00) of 30 mg mirtazapine. RESULTS Sleep was recorded on 2 drug-free baseline nights, the first 2 drug nights, and the last 2 drug nights. Eight of the 12 subjects showed increased PLMS after the first dose of mirtazapine. Frequency of PLMS was highest on the first drug night and attenuated over the course of the next 6 days. Three subjects reported transient restless legs symptoms. CONCLUSIONS Mirtazapine provoked PLMS in 67% of young healthy males. The effect was most pronounced in the first days. The possible role of serotonergic, noradrenergic and histaminergic mechanisms in mirtazapine-induced PLMS is discussed.

UI MeSH Term Description Entries
D008297 Male Males
D008803 Mianserin A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. Lerivon,Mianserin Hydrochloride,Mianserin Monohydrochloride,Org GB 94,Tolvon,Hydrochloride, Mianserin,Monohydrochloride, Mianserin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006304 Health Status The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures. General Health,General Health Level,General Health Status,Level of Health,Overall Health,Overall Health Status,General Health Levels,Health Level,Health Level, General,Health Levels,Health Status, General,Health Status, Overall,Health, General,Health, Overall,Level, General Health,Levels, General Health,Status, General Health,Status, Health,Status, Overall Health
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078785 Mirtazapine A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders. (N-Methyl-11C)mirtazapine,(S)-Mirtazapine,6-Azamianserin,Esmirtazapine,Norset,ORG 3770,ORG-3770,Org 50081,Remergil,Remeron,Rexer,Zispin,6 Azamianserin,ORG3770
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000929 Antidepressive Agents, Tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. Antidepressants, Tricyclic,Tricyclic Antidepressant,Tricyclic Antidepressant Drug,Tricyclic Antidepressive Agent,Tricyclic Antidepressive Agents,Antidepressant Drugs, Tricyclic,Agent, Tricyclic Antidepressive,Agents, Tricyclic Antidepressive,Antidepressant Drug, Tricyclic,Antidepressant, Tricyclic,Antidepressive Agent, Tricyclic,Drug, Tricyclic Antidepressant,Drugs, Tricyclic Antidepressant,Tricyclic Antidepressant Drugs,Tricyclic Antidepressants
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
June 2021, Sleep medicine clinics,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
October 1985, Archives of gerontology and geriatrics,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
June 2013, Sleep medicine,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
September 1998, The journals of gerontology. Series A, Biological sciences and medical sciences,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
June 2001, Psychiatry and clinical neurosciences,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
January 2010, Frontiers in neuroscience,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
September 2007, Journal of sleep research,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
November 1998, Revista de neurologia,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
March 2014, Sleep,
Stephany Fulda, and Stefan Kloiber, and Tatjana Dose, and Susanne Lucae, and Florian Holsboer, and Ludwig Schaaf, and Johannes Hennings
August 2009, Sleep,
Copied contents to your clipboard!